about
Molecular Basis of Prodrug Activation by Human Valacyclovirase, an -Amino Acid Ester HydrolaseResistance of human cytomegalovirus to the benzimidazole L-ribonucleoside maribavir maps to UL27Valganciclovir in the treatment of cytomegalovirus retinitis in HIV-infected patients.L-valine ester of cyclopropavir: a new antiviral prodrug.Valganciclovir: A new oral alternative for cytomegalovirus retinitis in human immunodeficiency virus-seropositive individuals.In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses.Oral and perioral herpes simplex virus type 1 (HSV-1) infection: review of its management.Role of a mutation in human cytomegalovirus gene UL104 in resistance to benzimidazole ribonucleosides.Inhibition of human cytomegalovirus replication by benzimidazole nucleosides involves three distinct mechanisms.Comprehensive Review in Current Developments of Benzimidazole-Based Medicinal Chemistry.Puromycin-sensitive aminopeptidase: an antiviral prodrug activating enzymeThe feasibility of enzyme targeted activation for amino acid/dipeptide monoester prodrugs of floxuridine; cathepsin D as a potential targeted enzyme.Synthesis and antiviral activity of some 2-substituted 3-formyl- and 3-cyano-5,6-dichloroindole nucleosides.Cellular p32 recruits cytomegalovirus kinase pUL97 to redistribute the nuclear lamina.Synthesis and antiviral evaluation of some novel tricyclic pyrazolo[3,4-b]indole nucleosides.Identification of a human valacyclovirase: biphenyl hydrolase-like protein as valacyclovir hydrolase.Stereoselective phosphorylation of cyclopropavir by pUL97 and competitive inhibition by maribavir.An Alternative Approach to Isoganciclovir: A Prominent Impurity in the Antiviral Drug Ganciclovir.Cytomegalovirus retinitis treated with valganciclovir in Wegener's granulomatosis.High dosage of oral valaciclovir as an alternative treatment of varicella zoster acute retinal necrosis syndrome.Reactivity of valganciclovir in aqueous solution.Neurotoxicity related to valganciclovir in a child with impaired renal function: usefulness of therapeutic drug monitoring.Enzymatic activation of double-targeted 5'-O-L-valyl-decitabine prodrug by biphenyl hydrolase-like protein and its molecular design basis.
P2860
Q27649800-9726453E-20E1-4D7A-97E2-0C8FD48584EDQ31011523-CB11B27C-D6BD-4C49-91B4-51412CBBFAB1Q33715300-6C6ABBBA-EA42-454F-B435-B6988AAEBE18Q34096928-91D85673-5AF1-4D25-BA60-7860D3BA82A6Q34834646-CBE1DD6F-9824-4769-B009-721A2349590CQ35103227-EDAC7D1F-055F-48FB-9244-D480B20A1328Q36478736-BB86B346-B4A5-4B79-881F-1AE3F2D08A26Q36944070-099C89B1-57D4-40A0-B91A-3FEE33B97D50Q37568962-2175F88B-72FE-4A19-AE61-AC74E14C1947Q38263434-A21494FD-C1DE-4F5C-B066-3C6266FFB080Q39341058-3611150B-3842-4683-A21A-0CFECBE28CD5Q39373589-F20843D5-0CC0-42A5-89C3-BD49C492E036Q40324876-1CA6F2C2-2BD9-475D-90C5-479CDA5BDCB7Q40405436-95D5E2B4-71AA-4E3B-A037-1EAED8501904Q40530573-7C40E8E4-6150-470E-9C7A-EBDB5ECB0219Q40649727-69642DF6-0039-42E7-9FFC-AC44B42E19B5Q42094851-C7677FA3-8A0F-4468-B97F-8AFCF98C2B16Q42120309-791969C2-5961-4A8B-ACE0-65727B8B9430Q42132159-2873A0D5-5B7D-4F91-9FFA-F8CBBBF6FCE8Q46388430-B254087B-7A29-4FE1-8E04-AB6B22EA988BQ46541829-96C15323-385D-4317-B159-A85A6B2E16E0Q46861990-B6605936-2E86-4AF2-9B94-9EF84A1F5C38Q48874796-FCA98F29-C6FB-445F-827A-6F8C6BA6B829
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Valganciclovir.
@ast
Valganciclovir.
@en
Valganciclovir.
@nl
type
label
Valganciclovir.
@ast
Valganciclovir.
@en
Valganciclovir.
@nl
prefLabel
Valganciclovir.
@ast
Valganciclovir.
@en
Valganciclovir.
@nl
P1433
P1476
Valganciclovir.
@en
P2093
P304
1145-50 ; discussion 1151-2
P356
10.2165/00003495-200161080-00013
P577
2001-01-01T00:00:00Z
P6179
1024058826